Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Senior Senators Seek Details On Government Audits Of 340B Entities

This article was originally published in The Pink Sheet Daily

Executive Summary

Top Republicans on two Senate health committees are joined by House members in seeking answers on an HHS review of entities receiving 340B drug discounts, including the process and consequences of audits and decertification.


Related Content

Hatch, Alexander Expected To Helm Health Panels In Senate
Sens. Hatch, Alexander Expected To Helm Health Panels In Senate
HRSA Pushes Ahead On 340B Hospital Audits, Gets $6M For Oversight
340B Orphan Drug Exclusion Seems Untenable, Sen. Hatch Tells HRSA
Walgreens Participation In 340B Program Probed By Sen. Grassley
340B Rule Clarifying Parameters For Discount Drug Program Is Planned By Year-End, HRSA Says
340B Drug Audits: HRSA Reviewing 51 Entities In 2012
Gaming 340B: Sen. Grassley Wants Answers On How A Hospital Bends Drug Discount Rules
Drug Audits Of 340B Providers Will Be Both Random And Targeted, HRSA Says
GAO And Legislators Pushing HHS For Stronger 340B Oversight





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts